A prospective study of cardiovascular disease in patients with Type 2 diabetes - 6.3 years of follow-up

By Riu F.R.   Vert I.S.   Martin A.L.   Gonzalez R.R.   Sala A.S.  

Journal of Diabetes and its Complications, Vol. 17, Iss. 5, 2003-09 ,pp. : 235-242

Elsevier

Access to resources Recommend Favorite

Ten‐Year Blood Pressure Trajectories, Cardiovascular Mortality, and Life Years Lost in 2 Extinction Cohorts: the Minnesota Business and Professional Men Study and the Zutphen Study

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 3, 2015-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)

By Raikou M.   McGuire A.   Colhoun H.   Betteridge D.   Durrington P.   Hitman G.   Neil H.   Livingstone S.   Charlton-Menys V.   Fuller J.  

Diabetologia, Vol. 50, Iss. 4, 2007-04 ,pp. : 733-740

Springer Publishing Company

Access to resources Recommend Favorite

Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicenter, randomized study

By Tonstad S.   Farsang C.   Klaene G.  

ACC Current Journal Review, Vol. 12, Iss. 5, 2003-09 ,pp. : 28-29

Elsevier

Access to resources Recommend Favorite

Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study

By  

Cerebrovascular Diseases, Vol. 27, Iss. 5, 2009-04 ,pp. : 509-518

Karger

Access to resources Recommend Favorite